SPY386.54-3.04 -0.78%
DIA314.19-1.40 -0.44%
IXIC13,358.79-230.04 -1.69%

DJ Regeneron's COVID-19 Antibody Drug Generated $145 Million In Sales In Q4 -- MarketWatch

· 02/05/2021 07:55
For more from MarketWatch: http://www.marketwatch.com/newsviewer

Shares of Regeneron Pharmaceuticals Inc. (REGN) gained 3.2% in premarket trading on Friday after the company said its COVID-19 antibody cocktail treatment generated $145.5 million in sales in the fourth quarter of 2020 as part of its earnings (http://www.marketwatch.com/story/regenerons-stock-rallies-after-profit-rises-well-above-expectations-while-revenue-matches-2021-02-05). The treatment, which received emergency use authorization in the U.S. in November, generated $185.7 million in sales for the full year. The U.S. government has agreed to buy up to about 1.5 million doses of the therapy, a purchase that brings in roughly $2.6 billion in revenue for Regeneron, the company said Friday. Regeneron's stock has rallied 34.0% over the past 12 months, while the broader S&P 500 is up 17.4%.

-Jaimy Lee

(END) Dow Jones Newswires

February 05, 2021 07:55 ET (12:55 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.